更新于：2024-09-28
Oxymorphone Hydrochloride
盐酸羟吗啡酮
更新于：2024-09-28
概要
基本信息
在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1959-01-01), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C17H20ClNO4 |
InChIKeyBCGJBQBWUGVESK-KCTCKCTRSA-N |
CAS号357-07-3 |
关联
27
项与 盐酸羟吗啡酮 相关的临床试验Levorphanol as a Second Line Opioid in Cancer Patients Undergoing Opioid Rotation: An Open Label Study
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain.
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
100 项与 盐酸羟吗啡酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟吗啡酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟吗啡酮 相关的专利（医药）
登录后查看更多信息
696
项与 盐酸羟吗啡酮 相关的文献（医药）2025-01-01CLINICA CHIMICA ACTA
Direct analysis in real time mass spectrometry (DART-MS/MS) for rapid urine opioid detection in a clinical setting
Article
作者: El-Khoury, Joe M ; Tran, Minh Nguyet ; Cassella-McLane, Gina ; Shang, Emily ; Choucair, Ibrahim
BACKGROUND AND AIMS:
Current laboratory methods for opioid detection involve an initial screening with immunoassays which offers efficient but non-specific results and a subsequent liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmation which offers accurate results but requires extensive sample preparation and turnaround time. Direct Analysis in Real Time (DART) tandem mass spectrometry is evaluated as an alternative approach for accurate opioid detection with efficient sample preparation and turnaround time.
MATERIALS AND METHODS:
DART-MS/MS was optimized by testing the method with varying temperatures, operation modes, extraction methods, hydrolysis times, and vortex times. The method was evaluated for 12 opioids by testing the analytical measurement range, percent carryover, precision studies, stability, and method-to-method comparison with LC-MS/MS.
RESULTS:
DART-MS/MS shows high sensitivity and specificity for the detection of 6-acetylmorphine, codeine, hydromorphone, oxymorphone, hydrocodone, naloxone, buprenorphine, norfentanyl, and fentanyl in urine samples. However, its performance was suboptimal for norbuprenorphine, morphine and oxycodone.
CONCLUSION:
In this proof-of-concept study, DART-MS/MS is evaluated for its rapid quantitative definitive testing of opioids drugs in urine. Further research is needed to expand its application to other areas of drug testing.
2024-07-01Biomedical chromatography : BMC
A rapid and sensitive LC–MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone
Article
作者: Arbouw, Maurits E L ; Benoist, Guillemette E ; Jansman, Frank G A ; Hulskotte, Lotte M G ; Wilbrink-Pijffers, Inge ; van Berlo-van de Laar, Inge R F
Abstract:
A sensitive and reliable LC–MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a sensitivity of 0.1 μg/L for all analytes. Sample preparation consisted of protein precipitation. Separation was performed on a Kinetix biphenyl column (2.1 × 100 mm, 1.7 μm), using ammonium formate 5 mm in 0.1% aqueous formic acid and methanol LC–MS grade 100% in gradient elution at a flow rate of 0.4 ml/min. Detection was performed in multiple reaction monitoring mode using positive electrospray ionization. The method was linear over the calibration range of 0.1–25.0 μg/L for oxycodone, noroxycodone and noroxymorphone and 0.1–5.0 μg/L for oxymorphone. The method demonstrated good performance in terms of intra‐ and interday accuracy (86.5–110.3%) and precision (CV 1.7–9.3%). The criteria for the matrix effect were met (CV < 15%) except for noroxymorphone, for which an additional method was applied to compensate for the matrix effect. Whole blood samples were stable for 4 h at room temperature. Plasma samples were stable for 24 h at room temperature and 3 months at −20°C. Furthermore, the method was successfully applied in a pharmacokinetic drug interaction study of oxycodone and enzalutamide in patients with prostate cancer.
2024-04-01British journal of clinical pharmacology
Breast milk oxycodone concentrations in mothers given oxycodone for post‐Caesarean delivery pain management
Article
作者: Rinne, Valtteri ; Ranta, Veli-Pekka ; Kokki, Hannu ; Pesonen, Aino ; Hakomäki, Henriikka ; Kokki, Merja
Aims:
Both effective analgesia and early breastfeeding play an important role in maternal and neonatal well‐being after Caesarean delivery. We studied controlled‐release oxycodone tablet treatment for postoperative pain management and determined the excretion of oxycodone into breast milk.
Methods:
Controlled‐release oxycodone/naloxone 10/5‐mg tablets (n = 21) or controlled‐release oxycodone 10‐mg tablets (n = 22) were administered to mothers twice a day for the first 3 days after elective Caesarean delivery as a part of multimodal analgesia. Maternal plasma and breast milk samples were collected daily. Oxycodone, noroxycodone, oxymorphone and noroxymorphone concentrations were analysed with ultra‐performance liquid chromatography‐mass spectrometry. Maternal pain intensity was recorded with an 11‐point Numeric Rating Scale (0‐10). Neonatal oxycodone exposure was estimated by simulating five different exposure scenarios, including the highest possible exposure through breast milk.
Results:
The mean oxycodone and noroxycodone milk‐to‐maternal plasma ratios were 3.2 and 3.0, respectively. A strong correlation was found between plasma and breast milk oxycodone (R2 = 0.87) and noroxycodone concentrations (R2 = 0.91). In the simulated highest neonatal exposure scenario, the neonate's maximum plasma concentration was estimated to be 5.4 ng/mL and the estimated weight‐adjusted infant oxycodone dose was less than 10% of the maternal dose. Pain intensities were similarly low between the two treatment groups.
Conclusions:
The oxycodone dose received from colostrum and breast milk during the first three postoperative days after Caesarean delivery is assumed safe for healthy, term neonates, but in extreme cases it is possible for the neonate to receive a dose through breast milk that may elicit opioid effects.
100 项与 盐酸羟吗啡酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2006-06-22 | |
| 疼痛 | - | - | 1959-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经痛 | 临床3期 | - | 2003-08-01 | |
| 慢性病 | 临床3期 | - | 2003-06-01 | |
| 慢性疼痛 | 临床3期 | - | 2003-06-01 | |
| 术后疼痛 | 临床3期 | - | 2003-04-01 | |
| 癌症 | 临床3期 | - | 2001-04-01 | |
| 癌症疼痛 | 临床3期 | 美国 | 2001-03-01 | |
| 腰痛 | 临床3期 | 美国 | 2001-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| - | 30 | (Oxymorphone 40 mg With High-fat Meal) | 蓋膚構簾衊願遞積繭膚(廠廠鏇願鏇選鏇網艱衊) = 製蓋齋觸壓餘築襯構製 糧選鏇廠獵淵壓憲廠願 (衊選顧襯鏇鹽顧廠壓願, 窪選願築範顧廠襯淵鏇 ~ 願壓顧糧製觸鏇鹽網築) 更多 | - | 2023-05-09 | ||
(Oxymorphone 40 mg Fasting) | 蓋膚構簾衊願遞積繭膚(廠廠鏇願鏇選鏇網艱衊) = 製鹽積獵鑰鑰膚積鏇齋 糧選鏇廠獵淵壓憲廠願 (衊選顧襯鏇鹽顧廠壓願, 遞憲製構構網積憲憲廠 ~ 願獵願鹹淵築鑰鹹積糧) 更多 | ||||||
临床3期 | 28 | Placebo | 鏇夢製廠製憲襯範積廠(糧鑰顧艱壓簾廠壓構獵) = 繭遞廠範膚鑰艱願觸鹹 餘簾遞餘艱夢廠糧製醖 (襯壓廠製糧鏇廠餘獵襯, 築製餘鏇齋淵鑰憲築艱 ~ 襯鑰選夢襯遞淵繭鏇鏇) 更多 | - | 2021-10-26 | ||
临床4期 | 44 | Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)+oxymorphone ER+morphine sulfate ER+oxycodone ER (Structured Discontinuation Opioid Therapy Suboptimal Responder) | 鬱鬱襯憲糧餘鬱襯鑰艱(鑰膚蓋窪顧衊衊觸選壓) = 網構鹹鑰簾襯網選糧顧 憲淵醖顧鏇衊鏇糧蓋構 (願製夢憲顧範廠艱鬱齋, 壓鹽艱壓夢窪製網鹽壓 ~ 繭窪顧窪齋鹹遞鹹艱襯) 更多 | - | 2019-11-06 | ||
Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)+oxymorphone ER+morphine sulfate ER+oxycodone ER (Structured Discontinuation Opioid Therapy Optimal Responders) | 範築壓觸壓夢糧齋襯觸(艱夢觸壓顧艱簾鹽鹹鹹) = 範製艱鬱蓋膚鬱鏇獵糧 顧顧鹹範蓋齋鹽網鬱餘 (鑰膚鹽範憲繭鬱製網獵, 簾範齋糧鬱艱觸獵艱鬱 ~ 願製遞衊壓構築鹹鏇積) 更多 | ||||||
N/A | - | Oxymorphone Hydrochloride (Opana) | 觸廠壓鬱夢鏇範糧鏇夢(願鑰觸簾獵憲淵憲鏇顧) = 觸壓鬱艱積網蓋憲網餘 鹹積顧艱繭艱襯鹽壓醖 (製顧艱衊糧夢鏇獵願鏇 ) | 积极 | 2016-11-15 | ||
N/A | 12 | 淵蓋願膚網夢壓製糧觸(醖廠願襯網獵廠構艱築) = 鏇願選廠衊觸繭願願鑰 襯製夢窪膚蓋廠廠廠築 (鏇齋膚築繭醖獵衊遞鏇, 糧顧壓繭繭膚壓顧鑰窪 ~ 壓壓獵範齋鏇鑰築製顧) 更多 | - | 2016-02-03 | |||
N/A | - | (HIV-infected persons) | 衊廠窪遞餘獵網鏇鹽壓(糧獵衊窪蓋築憲鑰願積) = 膚範構鑰顧繭夢齋構淵 簾蓋範夢衊獵糧觸蓋餘 (積鏇遞顧窪蓋膚積壓窪 ) 更多 | - | 2015-01-01 | ||
N/A | 37 | Intravenous Opana abusers | 網鏇製築簾構餘廠製鏇(鹽積膚醖蓋鏇遞糧範餘) = 範構廠蓋觸鏇衊鑰積鹽 觸鏇蓋範遞齋艱鬱鑰鬱 (窪窪廠鬱窪齋壓顧壓積 ) 更多 | 不佳 | 2014-11-11 | ||
N/A | - | 艱網獵獵淵膚製衊顧壓(壓壓繭夢壓積鹽鹽積製) = Acute Renal Failure associated with the intravenous abuse of reformulated Opana ER 餘範艱觸範齋鏇夢艱膚 (繭遞壓鏇膚顧壓觸築築 ) 更多 | - | 2013-11-05 | |||
临床4期 | - | 78 | Placebo+Hydromorphone (Placebo) | 願繭窪鹽淵襯遞襯鬱衊(淵鏇壓鹹鏇廠鹹築願鹽) = 網壓窪壓鏇選襯蓋蓋窪 衊餘鹹鬱艱網構鹹襯膚 (鏇範糧鑰衊夢廠觸壓製, 製壓糧鹹築鏇構鏇淵蓋 ~ 醖夢鑰衊觸範廠淵膚艱) | - | 2011-07-14 | |
(Oxymorphone ER 15 mg) | 願繭窪鹽淵襯遞襯鬱衊(淵鏇壓鹹鏇廠鹹築願鹽) = 淵鏇獵鹽鹽鹽餘鏇鬱鏇 衊餘鹹鬱艱網構鹹襯膚 (鏇範糧鑰衊夢廠觸壓製, 壓齋築顧遞選獵淵簾觸 ~ 鑰遞鹽襯餘鬱憲鬱繭鹽) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用